Corson JM - Brigham and Women’s Hospital
Mesothelioma Cancer Expert at Brigham and Women’s Hospital, Boston, MA
Mesothelioma Cancer Expert - Corson JM - Current Listing of Published Papers
The following is a listing of research papers by Corson JM in the field of mesothelioma cancer.
| Corson JM. Pathology of mesothelioma. Thorac Surg Clin. 2004 Nov;14(4):447-60. Pubmed 15559051 Department of Pathology, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. [partners.org] |
| Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):347-55. Pubmed 9352951 The Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA. |
| Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998 Mar;113(3):723-31. Pubmed 9515850 CALGB Statistical Center, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA. [ccstat.mc.duke.edu] |
| Samuels BL, Herndon JE 2nd, Harmon DC, Carey R, Aisner J, Corson JM, Suzuki Y, Green MR, Vogelzang NJ. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer. 1998 Apr 15;82(8):1578-84. Pubmed 9554537 Lutheran General Hospital, Park Ridge, Illinois 60068, USA. |
| Yogelzang NJ, Herndon JE 2nd, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997 Jun 1;79(11):2237-42. Pubmed 9179072 Section of Hematolog/Oncology, University of Chicago Medical Center, Illinois 60637-1470, USA. |
| Allen TC, Cagle PT, Churg AM, Colby TV, Gibbs AR, Hammar SP, Corson JM, Grimes MM, Ordonez NG, Roggli V, Travis WD, Wick MR. Localized malignant mesothelioma. Am J Surg Pathol. 2005 Jul;29(7):866-73. Pubmed 15958850 Department of Pathology, Baylor College of Medicine, Houston, TX, USA. |
| Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5. Pubmed 9869758 Division of Thoracic Surgery and the Department of Pathology, Brigham and Women’s Hospital, Boston, Mass 02115, USA. |
